Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biologics
FDA approves 2 therapeutic firsts
by Shi En Kim
November 25, 2022
| A version of this story appeared in
Volume 100, Issue 42
In a span of less than a week, the US Food and Drug Administration approved two new therapies, each of which is a first-in-class treatment for its respective disease. The first to receive the nod was Provention Bio’s teplizumab, an antibody that can delay the onset of type 1 diabetes in patients 8 years and older. Days later came approval for CSL Behring’s Hemgenix, the first gene therapy for hemophilia B. The one-time treatment restores peoples’ ability to produce proteins that help with blood clot formation.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X